News MaxCyte, Inc. Nasdaq

Equities

Market Closed - Nasdaq Other stock markets 01:30:00 22/06/2024 am IST			5-day change	1st Jan Change
4.24 ^USD	+1.92%		-13.47%	-9.79%

11/06	MaxCyte CEO Maher Masoud buys 100,000 shares	AN
11/06	Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing	MT

MaxCyte, Inc. - Grant of Options and Restricted Stock Units	17/06	AQ
MaxCyte, Inc. - Results of AGM	13/06	AQ
MaxCyte, Inc. - PDMR Dealing	12/06	AQ
MaxCyte CEO Maher Masoud buys 100,000 shares	11/06	AN
Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing	11/06	MT
MaxCyte : Participation in Upcoming Investor Conference	29/05	PU
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference	29/05	GL
MaxCyte inks deal with Legend Biotech for tech supply	23/05	AN
MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program	22/05	MT
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development	22/05	GL
MaxCyte, Inc. Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development	22/05	CI
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance	09/05	AQ
MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2024	09/05	AQ
MaxCyte Shares Rise Sharply After Q1 Results Beat	09/05	MT
MaxCyte shares rise amid double-digit revenue increase	08/05	AN
Earnings Flash (MXCT.L) MAXCYTE Posts Q1 Revenue $11.3M	08/05	MT
Earnings Flash (MXCT.L) MAXCYTE Reports Q1 Loss $-0.09	08/05	MT
MaxCyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Earnings Flash (MXCT) MAXCYTE Reports Q1 Revenue $11.3M, vs. Street Est of $7.5M	08/05	MT
Transcript : MaxCyte, Inc., Q1 2024 Earnings Call, May 07, 2024	08/05

No results for this search